Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Invest Dermatol ; 140(10): 1909-1918.e8, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32142797

RESUMO

We have shown previously that endocannabinoids promote sebaceous lipogenesis, and sebocytes are involved in the metabolism of the endocannabinoid-like substance oleoylethanolamide (OEA). OEA is an endogenous activator of GPR119, a recently deorphanized receptor, which currently is being investigated as a promising antidiabetic drug target. In this study, we investigated the effects of OEA as well as the expression and role of GPR119 in human sebocytes. We found that OEA promoted differentiation of human SZ95 sebocytes (elevated lipogenesis, enhanced granulation, and the induction of early apoptotic events), and it switched the cells to a proinflammatory phenotype (increased expression and release of several proinflammatory cytokines). Moreover, we could also demonstrate that GPR119 was expressed in human sebocytes, and its small interfering RNA-mediated gene silencing suppressed OEA-induced sebaceous lipogenesis, which was mediated via c-Jun N-terminal kinase, extracellular signal-regulated kinase 1/2, protein kinase B, and CRE-binding protein activation. Finally, our pilot data demonstrated that GPR119 was downregulated in the sebaceous glands of patients with acne, arguing that GPR119 signaling may indeed be disturbed in acne. Collectively, our findings introduce the OEA/GPR119 signaling as a positive regulator of sebocyte differentiation and highlight the possibility that dysregulation of this pathway may contribute to the development of seborrhea and acne.


Assuntos
Receptores Acoplados a Proteínas G/fisiologia , Glândulas Sebáceas/citologia , Glândulas Sebáceas/fisiologia , Diferenciação Celular/efeitos dos fármacos , Células Cultivadas , Citocinas/biossíntese , Endocanabinoides/farmacologia , Humanos , Ácidos Oleicos/farmacologia , PPAR alfa/fisiologia , Glândulas Sebáceas/imunologia , Transdução de Sinais/fisiologia
2.
J Cell Mol Med ; 23(9): 6203-6214, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31273921

RESUMO

Nicotinic acid (NA) activates hydroxycarboxylic acid receptor 2 (HCA2 ), and it is widely used in treating dyslipidaemias. Since its side effects include skin dryness, whereas its deficiency can be accompanied by dyssebacia, characterized by sebaceous gland enlargement, we asked if HCA2 is expressed on human sebocytes, and if NA influences sebocyte functions. By using human immortalized SZ95 sebocytes, we found that non-cytotoxic (≤100 µmol/L; MTT-assay) concentrations of NA had no effect on the homeostatic sebaceous lipogenesis (SLG; Nile Red), but normalized excessive, acne-mimicking SLG induced by several lipogenic agents (arachidonic acid, anandamide, linoleic acid + testosterone; Nile Red; 48-hr treatments). Moreover, it exerted significant anti-proliferative actions (CyQUANT-assay), and increased [Ca2+ ]IC (Fluo-4 AM-based Ca2+ -measurement). Although NA did not prevent the lipopolysaccharide-induced pro-inflammatory response (up-regulation [Q-PCR] and release [ELISA] of several pro-inflammatory cytokines) of the sebocytes, collectively, these data support the concept that NA may be effective in suppressing sebum production in vivo. While exploring the mechanism of the sebostatic actions, we found that sebocytes express HCA2 (Q-PCR, immunofluorescent labelling), siRNA-mediated silencing of which prevented the NA-induced Ca2+ -signal and the lipostatic action. Collectively, our data introduce NA, and HCA2 activators in general, as novel, potent and most likely safe sebostatic agents, with possible anti-acne potential.


Assuntos
Acne Vulgar/genética , Adenilil Ciclases/genética , Lipogênese/efeitos dos fármacos , Niacina/farmacologia , Glândulas Sebáceas/efeitos dos fármacos , Acne Vulgar/induzido quimicamente , Acne Vulgar/patologia , Ácido Araquidônico/farmacologia , Linhagem Celular , Citocinas/metabolismo , Dislipidemias/tratamento farmacológico , Dislipidemias/patologia , Humanos , Lipogênese/genética , Niacina/efeitos adversos , Niacina/genética , RNA Interferente Pequeno/genética , Glândulas Sebáceas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA